Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mTOR”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Early research (Phase 1)UnknownNCT02626507
What this trial is testing

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Hoffman Oncology 18
Testing effectiveness (Phase 2)WithdrawnNCT04482712
What this trial is testing

Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

Who this might be right for
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Respiratory FailureSars-CoV2
The University of Texas Health Science Center at San Antonio
Early research (Phase 1)Study completedNCT01482156
What this trial is testing

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Breast CancerMetastatic Renal Cell Carcinoma
Novartis Pharmaceuticals 46
Not applicableActive Not RecruitingNCT07151157
What this trial is testing

Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease

Who this might be right for
Adult-Onset Still's Disease
Ruijin Hospital 3
Post-approval studies (Phase 4)Study completedNCT01046045
What this trial is testing

Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients

Who this might be right for
Chronic Allograft Dysfunction in Renal Transplantation
Chinese University of Hong Kong 17